Daiichi Sankyo Company Stock News

TOKYO: Japan''s Nikkei share average tumbled more than 2% on Tuesday, extending losses to a fourth session, as sentiment soured further following an escalation in tensions around Ukraine. The Nikkei slid 2.17% to 26,327.90 by the midday break. The broader Topix slumped 1.76% to 1,877.01, also heading for a fourth straight session of losses. Only 11 of the Nikkei''s 225 constituent stocks rose, with one flat and the others falling. Healthcare was the sole sector to rise, pulled up by drugmaker Daiichi Sankyo surging about 10%, after positive results for the Erhertu cancer drug it co-developed with AstraZeneca. Consumer sectors were the worst performers, with basic materials and tech also suffering sizable losses. Tokyo shares end lower Japanese markets will be closed on Wednesday for a public holiday, putting market players in the mind to close out positions, traders said. Russian President Vladimir Putin ordered the deployment of troops to two breakaway regions in eastern Ukraine after recognising them as independent on Monday, accelerating a crisis the West fears could unleash a major war. "Risks around Ukraine have taken a turn for the worse, but at the same time, most of the potential near-term bad news has probably already been priced in by the market," said Makoto Kikuchi, chief executive of Myojo Asset Management.

First HER2-low metastatic breast cancer phase-III results for AstraZeneca and Daiichi Sankyos Enhertu offer potential to redefine how the disease is classified and treated The post Enhertu improves both progression-free and overall survival in Destiny-Breast04 trial in patients with HER2-low metastatic breast cancer appeared first on Express Pharma .

Daiichi Sankyo Co. posted its biggest gain in more than 18 months after the breast cancer drug its developing with AstraZeneca Plc helped patients with advanced disease live longer, potentially expanding treatment options for the most common cancer in women.

Daiichi Sankyo Co. posted its biggest gain in more than 18 months after the breast cancer drug its developing with AstraZeneca Plc helped patients with advanced disease live longer, potentially expanding treatment options for the most common cancer in women.

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.First HER2 low metastatic breast cancer phase 3 results for Daiichi Sankyo and AstraZenecas ENHERTU offer potential to redefine how the disease is classified and treatedPlans for global regulatory submissions are

Daiichi Sankyo Company, Limited (DSKYF) CEO Hiroyuki Okuzawa on Q3 2022 Results - Earnings Call Transcript

Daiichi Sankyo Co. (DSKYF):press release 9M Non-GAAP EPS of ¥49.16.Revenue of ¥810.96B (+9.8% Y/Y).

ST. GALLEN, Switzerland & SHIRLEY, N.Y.--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group and its partner American Regent, Inc., a Daiichi Sankyo Group company, today announced that they have reached settlement agreements with Mylan Laboratories Ltd., and Sandoz, Inc., that resolve the patent litigation brought in response to Abbreviated New Drug Applications seeking approval by the U.S. Food and Drug Administration to market a generic version of I

Kite, a Gilead Company, and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that YESCARTA (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, will be available to patients with relapsed or refractory large B-cell lymphomas in Japan through the first treatment center now authorized by Daiichi Sankyo. Kite and Daiichi Sankyo will also build on

Oral presentation at ASH 2021 features positive phase 2 data in Japanese patients with relapsed/refractory ATL Orphan Drug Designation granted with regulatory filing on track in Japan for FY2021 D

DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca''s ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, com

Shares of Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) dropped 5.8% during trading on Monday . The stock traded as low as $23.53 and last traded at $23.70. Approximately 44,415 shares traded hands during trading, a decline of 12% from the average daily volume of 50,335 shares. The stock had previously closed at $25.16. The firms fifty []

DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global breast cancer monoclonal antibodies market is expected to grow from $12.67 billion in 2020 to $13.76 billion in 2021 at a compound annual growth rate (CAGR) of 8.6%. The market is expected to reach $18.61 billion in 2025 at a CAGR of 8%. Major players in the breast cancer monoclonal antibodies (mAb

The global Human Combination Vaccines market is expected to reach US$ 7.8 Billion by 2027, with a CAGR of 9.7% from 2021 to 2027. Reduced adverse effects, increased research and studies to produce combination vaccines for additional diseases, and the